Scarica l'app Stockscreener
6.94
1.98%
-0.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAGE Giù?
Forum
Previsione
Precedente Chiudi:
$7.08
Aprire:
$7.07
Volume 24 ore:
2.06M
Relative Volume:
1.48
Capitalizzazione di mercato:
$424.54M
Reddito:
$91.06M
Utile/perdita netta:
$-503.14M
Rapporto P/E:
-0.8272
EPS:
-8.39
Flusso di cassa netto:
$-424.74M
1 W Prestazione:
-6.72%
1M Prestazione:
+23.71%
6M Prestazione:
-43.53%
1 anno Prestazione:
-73.32%
Intervallo 1D:
$6.71
$7.105
Intervallo di 1 settimana:
$6.71
$7.61
Portata 52W:
$4.62
$27.68
Sage Therapeutics Inc Stock (SAGE) Company Profile
Nome
Sage Therapeutics Inc
Settore
Industria
Telefono
617-299-8380
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Confronta SAGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
6.94 | 424.54M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-21 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-29 | Iniziato | Citigroup | Sell |
| 2024-05-29 | Iniziato | Robert W. Baird | Neutral |
| 2024-04-17 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-08-08 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Downgrade | Goldman | Buy → Neutral |
| 2023-08-08 | Downgrade | Needham | Buy → Hold |
| 2023-08-07 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-08-07 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Downgrade | Stifel | Buy → Hold |
| 2023-08-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-03-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-03-31 | Iniziato | Berenberg | Hold |
| 2021-11-02 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-16 | Downgrade | Citigroup | Buy → Neutral |
| 2021-04-07 | Iniziato | Piper Sandler | Overweight |
| 2021-02-26 | Downgrade | Mizuho | Buy → Neutral |
| 2021-02-25 | Reiterato | H.C. Wainwright | Neutral |
| 2021-02-02 | Ripresa | Raymond James | Mkt Perform |
| 2021-01-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-01-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Reiterato | H.C. Wainwright | Neutral |
| 2020-09-11 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-08-10 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-04-08 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-28 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-06 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-12-05 | Reiterato | Guggenheim | Buy |
| 2019-12-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-10-30 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-23 | Iniziato | Wedbush | Outperform |
| 2019-04-25 | Iniziato | Jefferies | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Sage Therapeutics Inc Borsa (SAGE) Ultime notizie
How To Trade (SAGE) - Stock Traders Daily
Sage sues Biogen after unsolicited takeover bid - pharmaphorum
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid - MSN
Sage sues Biogen in wake of $469M buyout offer: report (BIIB:NASDAQ) - Seeking Alpha
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1) - Bloomberg Law
BB Biotech AG Significantly Reduces Stake in Sage Therapeutics Inc - GuruFocus.com
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Biogen Offers to Buy Remaining Stake in Sage Therapeutics - MSN
Sage Therapeutics, Inc. (NASDAQ:SAGE) Short Interest Down 24.6% in December - MarketBeat
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders - Seeking Alpha
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen - MSN
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last? - MSN
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In - MSN
Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist - Yahoo Finance
Biogen proposes acquisition of partner Sage Therapeutics - MSN
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street - BioPharma Dive
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts - Benzinga
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge - Benzinga
Sage Therapeutics shares surge on unsolicited takeover bid from Biogen - Proactive Investors USA
Sage Therapeutics Stock Headed for Best Day in 5 Years - Schaeffers Research
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday - Benzinga
Sage Therapeutics Jumps on Biogen’s $469 Million Offer - Bloomberg
Biogen CEO confirms he’s shopping for biotechs: ‘We will be doing deals’ - The Boston Globe
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? - Yahoo Finance
Biogen Submits Offer to Buy Embattled Partner Sage - BioSpace
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
SAGE Therapeutics Outlines 2025 Strategy and Acquisition Proposal - TipRanks
Sage Therapeutics shares spike after Biogen offers to buy remaining stake - Investing.com
SAGE Therapeutics (SAGE) Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen (BIIB) (earlier) - StreetInsider.com
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - Benzinga
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen - BioSpace
Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Sage Therapeutics Unveils 2025 Strategy, Doubles Down on Postpartum Depression Drug ZURZUVAE - StockTitan
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Sage Therapeutics confirms $7.22 per share acquisition proposal from Biogen - MSN
Sage confirms unsolicited takeover bid from Biogen - The Pharma Letter
(SAGE) Investment Report - Stock Traders Daily
Sage confirms Biogen’s bid to acquire remaining stake - MSN
Sage stock gains on Biogen’s buyout offer (SAGE:NASDAQ) - Seeking Alpha
Biogen Moves to Acquire Sage Therapeutics Amid Pharmaceutical Market ShiftsNews and Statistics - IndexBox, Inc.
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - AccessWire
Deal Or No Deal? Sage Therapeutics Soars On Acquisition Proposal From Biogen - RTTNews
Biogen offers to buy out Sage Therapeutics - The Business Journals
Sage Therapeutics Receives Surprise $7.22 Per Share Acquisition Offer from Biogen - StockTitan
Biogen proposes to buy remaining stake in Sage in $442 million deal - Reuters
Biogen moves to acquire struggling partner Sage - FirstWord Pharma
Sage Therapeutics Inc Azioni (SAGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):